Biobot Surgical gets US FDA 510(k) clearance for new robotic assisted transperineal needle-guidance system, iSR'obot Mona Lisa 2.0 for prostate biopsy & cancer ablations

Biobot Surgical gets US FDA 510(k) clearance for new robotic assisted transperineal needle-guidance system, iSR'obot Mona Lisa 2.0 for prostate biopsy & cancer ablations

Biobot Surgical, a company focuses on medical robotics solutions, announced that the company has received US FDA 510(k) clearance for the iSR'obot Mona Lisa 2.0. The new robotic assisted transperineal needle-guidance system allows urologists to plan and position a single needle or multiple needles during image-guided diagnostic and interventional prostate procedures. The iSR'obot Mona Lisa 2.0 is the latest addition to Biobot Surgical's iSR'obot Mona Lisa product portfolio. "The Mona Lisa system was conceptualized and engineered to position biopsy or treatment needles transperineally. The advantages of transperineal procedures are lower infection rates and better coverage of the anterior zone compared to transrectal procedures. In addition, most ablation procedures are also carried out transperineally. The Mona Lisa system simplifies needle positioning by providing robotic assisted guidance for the insertion." said Sim Kok Hwee, CEO of Biobot Surgical. The iSR'obot Mona Lisa 2.0 automatically supports needle positioning during transperineal prostate biopsy and prostate cancer ablation based on a customized needle plan. The new features include: A detachable needle guide that holds a biopsy needle or multiple ablation needles; Visualization and planning of the needle locations for a prostate cancer ablation procedure; Ability to re-adjust a target location when the needle deflects. The second-generation iSR'obot Mona Lisa system retains the MR-ultrasound image-fusion prostate biopsy technology. The robotic system's proprietary dual-cone needle trajectory technology enables the extraction of multiple biopsy cores through the same needle entry points. The first-generation iSR'obot Mona Lisa is marketed in Europe, Australia, and Asia. Clinical studies have demonstrated that iSR'obot Mona Lisa has a clinically significant prostate cancer detection rate of 81 percent higher than cognitive fusion biopsy. Clinical data also shows that the transperineal, dual-cone needle trajectory technology minimizes infection complications. Biobot Surgical Pte. Ltd is headquartered in Singapore and focuses on medical robotics solutions. The company is expanding its core technology in precision needle positioning to address comprehensive prostate cancer care to improve patient prostate cancer outcomes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!